Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China

机译：用Palbociclib加内分泌治疗和随后治疗治疗130例激素受体阳性和人表皮生长因子受体2阴性转移性乳腺癌患者的临床结果和疗法：中国的真实单中心回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
作者
Chang Liu; Ting Li; Zhonghua Tao; Jun Cao; Leiping Wang; Jian Zhang; Biyun Wang; Xichun Hu;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类
关键词

机译：乳腺肿瘤;细胞周期蛋白依赖性激酶抑制剂蛋白;务实的临床试验作为主题;

相似文献

外文文献
中文文献
专利

1. WHICH IS MORE BENEFICIAL AS AN INITIAL THERAPY FOR THE FIRST DISTANT METASTASIS OF BREAST CANCER: CHEMOTHERAPY OR ENDOCRINE THERAPY FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER PATIENTS? A SINGLE-CENTER STUDY [J] . Yamamura Jun, Shunji Kamigaki, Masaki Tsujie, The Breast : . 2015,第Suppla3期

机译：对于乳腺癌的首次远处转移，哪种疗法更有益：对于激素受体阳性，人表皮生长因子受体2阴性的乳腺癌患者，化学疗法或内分泌疗法是什么？单中心研究
2. WHICH IS MORE BENEFICIAL AS AN INITIAL THERAPY FOR THE FIRST DISTANT METASTASIS OF BREAST CANCER: CHEMOTHERAPY OR ENDOCRINE THERAPY FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER PATIENTS? A SINGLE-CENTER STUDY [J] . Yamamura Jun, Shunji Kamigaki, Masaki Tsujie, The Breast : . 2015,第Suppla3期

机译：哪种更有益作为乳腺癌第一个远处转移的初始治疗：对激素受体阳性的化疗或内分泌治疗，人表皮生长因子受体2阴性乳腺癌患者？单一学习
3. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：珍珠研究结果（Geicam / 2013-02_cecog / BC.1.3.006）：帕尔巴昔米尔（PAL）与内分泌治疗（ET）与己酮受体（HR） - 阳性/人类组合的第3阶段试验表皮生长因子受体（她）2阴性转移性乳腺癌（MBC）患者（PTS），其疾病在芳香酶抑制剂上进行（AIS）
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis [O] . Siqi Liu, Xin Sun, Xiaohui Xu, 2020

机译：激素受体阳性和人表皮生长因子受体2阴性局部晚期或转移性乳腺癌中内分泌治疗的比较：网络元分析
7. Use of molecular targeted therapy for hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer in real-world clinical practice [O] . Satoko Nakano, Yoshimi Imawari, Akemi Mibu, 2021

机译：在现实世界临床实践中使用分子靶向治疗激素受体阳性，人表皮生长因子2阴性转移性乳腺癌

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China

著录项

相似文献

相关主题

期刊订阅